Latest Insider Transactions at Novo Cure LTD (NVCR)
This section provides a real-time view of insider transactions for Novo Cure LTD (NVCR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NovoCure Ltd to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NovoCure Ltd's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 01
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
6,830
+11.92%
|
-
|
|
Oct 13
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
6,754
-13.41%
|
$513,304
$76.01 P/Share
|
|
Oct 06
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
6,754
-11.82%
|
$567,336
$84.37 P/Share
|
|
Sep 29
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
6,754
-10.57%
|
$520,058
$77.35 P/Share
|
|
Sep 22
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
6,754
-9.56%
|
$520,058
$77.0 P/Share
|
|
Sep 15
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
12,271
-7.7%
|
$1,079,848
$88.65 P/Share
|
|
Sep 15
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
5,517
+6.24%
|
$38,619
$7.15 P/Share
|
|
Sep 09
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
1,863
-2.17%
|
$163,944
$88.0 P/Share
|
|
Sep 06
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
1,384
-1.58%
|
$107,952
$78.57 P/Share
|
|
Sep 02
2022
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
269
-0.32%
|
$21,251
$79.04 P/Share
|
|
Sep 02
2022
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
296
-0.18%
|
$23,384
$79.04 P/Share
|
|
Sep 02
2022
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
885
-1.21%
|
$69,915
$79.04 P/Share
|
|
Sep 02
2022
|
William Patrick Burke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
718
-1.28%
|
$56,722
$79.04 P/Share
|
|
Sep 02
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
584
-0.66%
|
$46,136
$79.04 P/Share
|
|
Sep 01
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
14,212
-1.24%
|
$1,094,324
$77.43 P/Share
|
|
Aug 03
2022
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,959
-8.73%
|
$429,048
$72.54 P/Share
|
|
Aug 02
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
414
-0.4%
|
$28,566
$69.66 P/Share
|
|
Aug 02
2022
|
William F Doyle Executive Chairman |
SELL
Open market or private sale
|
Direct |
837
-0.15%
|
$57,753
$69.66 P/Share
|
|
Aug 02
2022
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,122
+8.86%
|
$498,540
$70.2 P/Share
|
|
Aug 02
2022
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
437
-1.25%
|
$30,153
$69.66 P/Share
|
|
Jul 05
2022
|
Uri Weinberg Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
281
+0.56%
|
$16,579
$59.08 P/Share
|
|
Jul 05
2022
|
Pritesh Shah Chief Growth Officer |
BUY
Grant, award, or other acquisition
|
Direct |
312
+0.37%
|
$18,408
$59.08 P/Share
|
|
Jul 05
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
312
+0.3%
|
$18,408
$59.08 P/Share
|
|
Jul 05
2022
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
218
+0.13%
|
$12,862
$59.08 P/Share
|
|
Jul 05
2022
|
Asaf Danziger Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
276
+1.99%
|
$16,284
$59.08 P/Share
|
|
Jul 05
2022
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
251
+0.38%
|
$14,809
$59.08 P/Share
|
|
Jul 05
2022
|
William Patrick Burke Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
213
+0.38%
|
$12,567
$59.08 P/Share
|
|
Jul 05
2022
|
Ely Benaim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
222
+0.63%
|
$13,098
$59.08 P/Share
|
|
Jul 05
2022
|
Barak Ben Arye General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
144
+0.84%
|
$8,496
$59.08 P/Share
|
|
Jun 10
2022
|
Jeryl L Hilleman |
SELL
Open market or private sale
|
Direct |
407
-13.82%
|
$28,083
$69.61 P/Share
|
|
Jun 08
2022
|
Gabriel Leung |
BUY
Grant, award, or other acquisition
|
Direct |
2,427
+3.12%
|
-
|
|
Jun 08
2022
|
David Hung |
BUY
Grant, award, or other acquisition
|
Direct |
2,427
+20.98%
|
-
|
|
May 11
2022
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,135
-5.77%
|
$130,235
$61.25 P/Share
|
|
May 10
2022
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,070
-5.3%
|
$134,550
$65.16 P/Share
|
|
Mar 09
2022
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
3,669
-4.22%
|
$260,499
$71.19 P/Share
|
|
Mar 08
2022
|
William F Doyle Executive Chairman |
SELL
Open market or private sale
|
Direct |
2,385
-0.43%
|
$166,950
$70.1 P/Share
|
|
Mar 08
2022
|
Todd Christopher Longsworth General Counsel |
SELL
Open market or private sale
|
Direct |
2,339
-3.61%
|
$163,730
$70.1 P/Share
|
|
Mar 08
2022
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
759
-1.23%
|
$53,130
$70.1 P/Share
|
|
Mar 08
2022
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,923
-1.74%
|
$204,610
$70.1 P/Share
|
|
Mar 08
2022
|
William Patrick Burke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,037
-1.82%
|
$72,590
$70.1 P/Share
|
|
Mar 08
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
744
-0.72%
|
$52,080
$70.1 P/Share
|
|
Mar 08
2022
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
2,481
-2.94%
|
$173,670
$70.1 P/Share
|
|
Mar 07
2022
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
5,294
-5.9%
|
$365,286
$69.55 P/Share
|
|
Mar 04
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
555
-0.54%
|
$38,850
$70.41 P/Share
|
|
Mar 04
2022
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,569
-1.51%
|
$179,830
$70.41 P/Share
|
|
Mar 04
2022
|
William Patrick Burke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,026
-1.77%
|
$71,820
$70.41 P/Share
|
|
Mar 04
2022
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,510
-3.37%
|
$105,700
$70.41 P/Share
|
|
Mar 04
2022
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
4,546
-2.44%
|
$322,766
$71.88 P/Share
|
|
Mar 04
2022
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
556
-0.89%
|
$38,920
$70.41 P/Share
|
|
Mar 04
2022
|
Todd Christopher Longsworth General Counsel |
SELL
Open market or private sale
|
Direct |
1,973
-2.95%
|
$138,110
$70.41 P/Share
|